Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. O...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Schroth, Werner, Goetz, Matthew P., Hamann, Ute, Fasching, Peter A., Schmidt, Marcus, Winter, Stefan, Fritz, Peter, Simon, Wolfgang, Suman, Vera J., Ames, Matthew M., Safgren, Stephanie L., Kuffel, Mary J., Ulmer, Hans Ulrich, Boländer, Julia, Strick, Reiner, Beckmann, Matthias W., Koelbl, Heinz, Weinshilboum, Richard M., Ingle, James N., Eichelbaum, Michel, Schwab, Matthias, Brauch, Hiltrud
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3909953/
https://ncbi.nlm.nih.gov/pubmed/19809024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2009.1420
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi